Design Therapeutics Inc

For the period ended Sep 30, 2024. Filed Nov 7, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 7, 2024

DSGN$10.21+5.6%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Balance Sheets

(in thousands, except share and par value data)

	September 30,	December 31,
	2024	2023
(unaudited)
Assets
Current assets:
Cash and cash equivalents	$30,328	$21,200
Investment securities	223,746	260,598
Prepaid expenses and other current assets	3,168	2,786
Total current assets	257,242	284,584
Property and equipment, net	1,559	1,691
Right-of-use asset, related party	2,401	2,938
Other assets	427	430
Total assets	$261,629	$289,643
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$1,470	$1,940
Accrued expenses and other current liabilities (including related party amounts of $778 and $716 respectively)	5,962	7,682
Total current liabilities	7,432	9,622
Operating lease liability, net, related party	1,744	2,334
Total liabilities	9,176	11,956
Commitments and contingencies (See Note 8)
Stockholders’ equity:
Common stock, $0.0001 par value; 200,000,000 shares authorized at September 30, 2024 and December 31, 2023; 56,621,037 and 56,473,598 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively	6	6
Additional paid-in capital	465,096	455,245
Accumulated deficit	(213,563)	(177,626)
Accumulated other comprehensive income	914	62
Total stockholders’ equity	252,453	277,687
Total liabilities and stockholders’ equity	$261,629	$289,643

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.